Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Tian

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Arxiv|April 17, 2026
An Open-Source, Open Data Approach to Activity Classification from Triaxial Accelerometry in an Ambulatory SettingSepideh Nikookar, Edward Tian, Harrison Hoffman, et al.
Plos One|June 14, 2013
Effects of AgRP inhibition on energy balance and metabolism in rodent modelsRoxanne Dutia, Andrea J Kim, Matthew Modes, et al.
The Oncologist|June 20, 2023
Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I TrialJunning Cao, Hongqian Guo, Dongmei Ji, et al.
Cancer|January 31, 2023
A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumorsBo Gao, Mark Voskoboynik, Adam Cooper, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Arxiv|April 17, 2026
An Open-Source, Open Data Approach to Activity Classification from Triaxial Accelerometry in an Ambulatory SettingSepideh Nikookar, Edward Tian, Harrison Hoffman, et al.
Plos One|June 14, 2013
Effects of AgRP inhibition on energy balance and metabolism in rodent modelsRoxanne Dutia, Andrea J Kim, Matthew Modes, et al.
The Oncologist|June 20, 2023
Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I TrialJunning Cao, Hongqian Guo, Dongmei Ji, et al.
Cancer|January 31, 2023
A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumorsBo Gao, Mark Voskoboynik, Adam Cooper, et al.
Pageof 1